

## ABBV-303

Cat. No.:	HY-P990306
Target:	c-Met/HGFR; ADC Antibody
Pathway:	Protein Tyrosine Kinase/RTK; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

ABBV-303 is a multi-specific NK cell antibody targeting c-Met designed based on TriNKET technology for natural killer (NK) cell redirection therapy. The ABBV-303 antibody consists of three functional arms, a single-chain variable fragment (scFV) targeting c-Met, a Fab arm targeting NKG2D, and an Fc fragment targeting NK cell CD16a<sup>[1]</sup>.

#### In Vitro

Introduction of the three functional arms of ABBV-303<sup>[1]</sup>:  
(1) Single-chain variable fragment (scFV): scFV based on ABT-700 (HY-P99391), also c-Met< /b> Targeted antibody-drug conjugates (ADCs) The consensus fragment of ABBV-400 and Teliso-V;  
(2) Fab arm: targeting NKG2D, used to bind and activate NK cells expressing NKG2D CD8<sup>+</sup> T cells;  
(3) Conventional Fc fragment: heterodimeric IgG1 Fc, targeting CD16a on NK cells, and also used to connect the other two components of ABBV-303 A functional arm.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Stone J, et al. Abstract ND01: ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors[J]. Cancer Research, 2024, 84(7\_Supplement): ND01-ND01.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA